| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fd5eb30cd07e373f2a122294e6086b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b0dc01226de91c738c3b752e2e6db53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73514a82d40d7976a333e6e11039ae41 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca4181387a73a722821ea3ed4aef5815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2fc3b217393b22001bb1901a21da0df |
| publicationDate |
2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007117121-A2 |
| titleOfInvention |
Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
| abstract |
The present invention relates to a small interfering RNA (siRNA) suppressing the expression of adenine nucleotide translocator 2 (ANT2) gene and an anticancer agent containing the same. Particularly, the invention relates to ANT2 siRNA comprising a sense sequence selected from the nucleotide sequences of ANT2 mRNA, a hairpin loop sequence and an antisense sequence binding complementarily to the said sense sequence and an anticancer agent containing the same. ANT2 siRNA of the present invention inhibits the expression of ANT2 gene, suggesting that it inhibits the growth of cancer cells exhibiting high level of ANT2. Therefore, ANT2 siRNA of the invention can be effectively used for gene therapy for cancer treatment and further prevents the anticancer effect from decreasing by anticancer drug resistance of cancer cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2675468-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109913455-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2675468-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009113295-A1 |
| priorityDate |
2006-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |